Large Allergan Inc. Investor Sells Most Of Stake

Published: Jul 22, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Allergan's largest holder as of the end of March, Capital Research and Management, has sold nearly all of its stake in the company, The Wall Street Journal reported Monday. According to people close to the matter, Capital Research and Management sold the shares, representing a 6.3-percent stake, after meeting with Allergan CEO David Pyott. Sources noted that the sale indicates that Capital Research and Management didn't see Allergan's share price rising much above Valeant Pharmaceuticals' $53-billion hostile offer.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news